Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-11-12

Clinical Trial Update: Optimal Treatment for Recurrent Clostridium Difficile [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating optimal treatment for recurrent Clostridioides difficile infection has terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dificid (fidaxomicin)
  • Vancocin (vancomycin)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Clostridium, Difficile | Phase 4 | Status: TERMINATED | Results posted: 2025-11-12